Chasing Clarity: Health & Fitness Podcast EP. 123: OZEMPIC & WEGOVY DEEP DIVE: THE SCIENCE OF GLP-1 AGONISTS WITH DR. SCOTT STEVENSON
Aug 15, 2024
Dr. Scott Stevenson, a physician with expertise in metabolism and obesity pharmacology, joins to unravel the complexities of GLP-1 agonists like semaglutide. They discuss the physiological actions of GLP-1, its role in appetite suppression, and how it affects gastric emptying. Scott highlights the positive metabolic effects and weight loss potential, while also addressing concerns about lean mass loss and weight regain after discontinuation. The conversation emphasizes the importance of combining GLP-1s with nutrition coaching for lasting results.
AI Snips
Chapters
Transcript
Episode notes
Pair Drugs With Behavioral Support
- If your physician prescribes GLP-1 therapy, secure referrals to a nutritionist and exercise coach.
- Build behavioral support because the drug reduces hunger but doesn't teach maintenance skills.
Pharmacokinetics Matter
- Endogenous GLP-1 has a ~2-minute half-life and is rapidly degraded by DPP-4.
- Semaglutide is modified to resist degradation, extending its half-life to allow once-weekly dosing.
Insulin Is A Satiety Hormone
- Insulin functions as a satiety signal and often correlates with greater post-meal fullness.
- GLP-1 drugs increase insulin response around meals, contributing to appetite suppression.